Physician profile
Arnold E Drummond
NPI 1245209618
$5,805.50
in general payments reported to CMS, 2019-2025
42 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,282 · 2020: $176 · 2021: $99.36 · 2022: $621 · 2023: $858 · 2024: $1,439 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,627.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,117.37 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $848.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $674.20 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $515.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.38 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $365.24 | 2019-2025 | Mounjaro, Zepbound, Taltz |
| Novartis Pharmaceuticals Corporation | $207.86 | 2019-2025 | |
| Amgen INC. | $167.58 | 2019-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $136.29 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $135.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.27 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $98.22 | 2019-2023 | Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $92.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.56 | 2019-2020 | |
| Astellas Pharma US INC | $88.76 | 2019-2025 | Veozah |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Drummond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.